2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several challenges: declining revenues due to competition, regulatory hurdles, and limited patient access. Restructuring efforts aim to save costs, but involve significant one-time expenses, creating short-term financial strain. While ABECMA's safety and efficacy are competitive, the market remains challenging. Despite potential growth from label expansion, the current competitive pressure and regulatory complexities present risks. The Q&A section further highlights management's vague responses on utilization trends, adding to uncertainties. These factors suggest a negative outlook for the stock price in the short term.
Key Financial Performance
ABECMA US revenues (Q4 2023) $56 million, a decline due to ongoing competition from other BCMA targeted therapies.
Collaborative arrangement revenue (Q4 2023) $2 million, related to collaboration with BMS.
Collaborative arrangement revenue (Full Year 2023) $50 million, related to collaboration with BMS.
Cash, cash equivalents, and marketable securities (End of 2023) $221.8 million.
Annual savings from restructuring (2024) Approximately $150 million.
Annual savings from restructuring (2025) Approximately $200 million, inclusive of one-time cash restructuring costs of approximately $8 million to $10 million.
Expected cash runway Beyond 2027.
Path to potential breakeven By 2025, obviating the need to seek funding from the capital market in the foreseeable future.
Operating Highlights
ABECMA: The company is focused on ABECMA and is preparing for a supplemental Biologics License Application (sBLA) in the third-line treatment setting, with positive data from the KarMMA-3 study.
Market Expansion: Regulatory approvals for ABECMA in Japan, Switzerland, and a positive CHMP opinion in the EU, indicating potential for growth in the US market.
Cost Structure: Expected annual savings of approximately $150 million in 2024 and $200 million in 2025 due to restructuring measures.
Strategic Shift: Entered into an asset purchase agreement with Regeneron to acquire the research and development pipeline, focusing solely on ABECMA.
Risk or Challenges
Competitive Pressures: The decline in fourth-quarter sales of ABECMA was attributed to ongoing competition from other BCMA targeted therapies, which is expected to continue impacting commercial performance until the potential label expansion to the third-line plus setting.
Regulatory Issues: The company is preparing for an upcoming ODAC meeting regarding the sBLA for ABECMA, with the FDA focusing on overall survival data from the KarMMA-3 study, which could influence future approvals.
Supply Chain Challenges: The company is working to ensure timely delivery of ABECMA to patients, indicating potential supply chain challenges in meeting anticipated demand.
Economic Factors: The restructuring measures are expected to yield annual savings of approximately $150 million in 2024 and $200 million in 2025, which reflects the company's response to economic pressures and the need for cost management.
Guidance & Outlook
Strategic Focus: 2seventy bio has embarked on a new strategic path focused solely on ABECMA.
Asset Purchase Agreement: Entered into an asset purchase agreement with Regeneron to acquire the research and development pipeline, expected to close in the first half of 2024.
Regulatory Engagement: Preparing for the sBLA discussion at the upcoming ODAC meeting, focusing on overall survival data from the KarMMA-3 study.
Commercial Strategy: Efforts to expand site footprint and differentiate ABECMA's safety and efficacy profile with real-world data.
Revenue Expectations: Fourth quarter ABECMA US revenues were $56 million, with expectations for growth as the label expands to the third-line plus setting.
Collaborative Revenue Growth: Anticipate collaborative arrangement revenue to grow meaningfully as ABECMA returns to commercial growth.
Cost Savings: Expected annual savings of approximately $150 million in 2024 and $200 million in 2025 due to restructuring measures.
Cash Runway: Cash runway expected to extend beyond 2027, with a path to potential breakeven by 2025.
Shareholder Return Plan
Annual Savings from Restructuring Measures: We expect annual savings of approximately $150 million in 2024 and approximately $200 million in 2025.
Cash Runway: We ended the year with $221.8 million of cash, cash equivalents, and marketable securities, and expect our cash runway to go beyond 2027.
Potential Breakeven: We see a path to potential breakeven by 2025, obviating the need to seek funding from the capital market in the foreseeable future.
Key Q&A
Earnings Word Cloud
TSVT Transcript
The earnings call reflects strong financial performance with a 42% revenue growth for Abecma, improved margins, and significant cost reductions. The strategic focus on Abecma and partnerships with Regeneron and Novo Nordisk are promising. Despite competitive pressures and seasonality, the company anticipates breakeven by 2025, with a reduced breakeven point. The Q&A highlights strong demand and improved manufacturing capacity. While there are risks, the overall sentiment is positive, suggesting a likely stock price increase.
The earnings call presents a positive sentiment with a focus on strategic realignment and a leaner cost structure. Despite regulatory and market risks, the company achieved profitability and reduced operating expenses significantly. The Q&A section highlights positive early experiences with ABECMA and potential growth. While guidance is not yet provided, the revised net cash spend range and expectation of breakeven by 2025 are promising. The stock price is likely to see a positive movement, considering the reduced financial risk and operational efficiency improvements.
The earnings call reveals several challenges: declining revenues due to competition, regulatory hurdles, and limited patient access. Restructuring efforts aim to save costs, but involve significant one-time expenses, creating short-term financial strain. While ABECMA's safety and efficacy are competitive, the market remains challenging. Despite potential growth from label expansion, the current competitive pressure and regulatory complexities present risks. The Q&A section further highlights management's vague responses on utilization trends, adding to uncertainties. These factors suggest a negative outlook for the stock price in the short term.
TSVT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
